The relationship between diuretic dose, and the haemodynamic response to captopril in patients with cardiac failure

A D Flapan1, E Davies, B C Williams

  • 1Department of Medicine, Western General Hospital, Edinburgh, Scotland.

Insights

Higher diuretic doses enhance captopril's hemodynamic effects in heart failure patients. Reducing diuretic dosage before captopril may prevent severe hypotension, optimizing treatment for cardiac failure.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Chronic cardiac failure management often involves diuretics and ACE inhibitors like captopril.
  • The interaction between diuretic dosage and captopril's hemodynamic effects requires further elucidation.

Purpose of the Study:

  • To assess the impact of varying diuretic doses on the hemodynamic response to captopril in patients with chronic cardiac failure.

Main Methods:

  • Nine patients with chronic cardiac failure received intravenous captopril under two conditions: low-dose and high-dose diuretic regimens.
  • Plasma hormone concentrations (renin, angiotensin, aldosterone) were measured to assess the renin-angiotensin-aldosterone system activity.

Main Results:

  • Higher diuretic doses correlated with increased renin-angiotensin-aldosterone system activity.
  • The hemodynamic response to captopril was significantly greater in patients on high-dose diuretic regimens.
  • No significant correlation was found between baseline hormone levels and the magnitude of hemodynamic changes.

Conclusions:

  • Increased loop diuretic dosage potentiates the hemodynamic effects of captopril in cardiac failure.
  • Reducing diuretic dosage before initiating captopril may mitigate the risk of first-dose hypotension.

Related Concept Videos

Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.8K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
671
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
371
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626